Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma

Table 1

Correlation between SNORA71A expression and clinicopathological features in HCC patients.

Characteristics	Total	SNORA71A expression		value
		Low ()	High ()
Age, ys				0.138
<60	85	46 (0.697)	39 (0.591)
≥60	47	20 (0.303)	27 (0.409)
Gender				0.212
Female	16	6 (0.091)	10 (0.152)
Male	116	60 (0.909)	56 (0.848)
Hepatitis B				0.310
Positive	113	58 (0.879)	11 (0.167)
Negative	19	8 (0.121)	55 (0.833)
Cirrhosis				0.361
Present	79	38 (0.576)	41 (0.621)
Absent	53	28 (0.424)	25 (0.379)
AFP (ng/l)				0.429
<400	82	42 (0.636)	40 (0.606)
≥400	50	24 (0.364)	26 (0.394)
Tumor diameter				0.005
<5 cm	34	10 (0.152)	24 (0.364)
≥5 cm	98	56 (0.848)	42 (0.636)
Multiple lesions				0.017
Present	22	16 (0.242)	6 (0.091)
Absent	110	50 (0.758)	60 (0.909)
Vessel carcinoma embolus				0.160
Present	34	20 (0.303)	14 (0.212)
Absent	98	46 (0.697)	52 (0.788)
Microvascular invasion				0.500
Present	7	4 (0.061)	3 (0.045)
Absent	125	62 (0.939)	63 (0.955)
Capsular invasion				0.015
Present	49	31 (0.470)	18 (0.273)
Absent	83	35 (0.530)	48 (0.727)
Differentiation				0.027
Low	70	41 (0.621)	29 (0.439)
High/moderate	62	25 (0.379)	37 (0.561)
TNM stage				0.004
I~II	91	38 (0.576)	53 (0.803)
III~IV	41	28 (0.424)	13 (0.197)

AFP = alpha fetal protein; TNM = tumor-node-metastasis; ; values are or (%).